ALSO NOTED: Chlorogen raises $6M in VC; Antisense receives approval to restart Phase IIa trial; and much more...

> Chlorogen has raised $6 million series B funding. The company will use the investment to finance development of its lead product candidates, which include protein-based therapies for gynecological cancers. Release

> Antisense Therapeutics has received approval from the Ethics Committee of the University of Essen in Germany to restart the Phase IIa trial of its antisense compound, ATL1102, for patients with relapsing-remitting multiple sclerosis. Release

> The FDA is questioning whether GlaxoSmithKline's Xenical can be sold safely over the counter. Report

> Takeda has begun Phase II clinical studies of ATL-962, a treatment for obesity and related diseases. Release

> SuperGen has withdrawn its marketing application for Orathecin from the European Medicines Agency (EMEA). Orathecin is an investigational drug for the treatment of pancreatic cancer. Release

And Finally... Isn't it nice to know your cell phone won't give you brain cancer? Article

Suggested Articles

German scientists are targeting a protein-cutting enzyme that many viruses, including the coronavirus COVID-19, need to replicate.

The 100 largest companies trading on the London Stock Exchange have boosted the percentage of women on their boards, but has life sciences kept pace?

In this week's EuroBiotech Report, Bicycle lands Genentech collaboration, GSK inks COVOD-19 adjuvant deal and Grifols buys antibiotic assets.